OncoMatch/Clinical Trials/NCT05141149
First in Human Phase1/2a Clinical Trial of Anti-PAUF Monoclonal Antibody PBP1510 in Patients With Pancreatic Cancer
Is NCT05141149 recruiting? Yes, currently enrolling (Jun 2026). This Phase 1/2 trial studies multiple treatments including PBP1510 (400mg/16mL) and Gemcitabine (1000 mg/m^2) for pancreatic cancer.
Treatment: PBP1510 (400mg/16mL) · Gemcitabine (1000 mg/m^2) — The first in human clinical study is planned as an open-label, dose-escalation, and dose-expansion, multicentre, two-part, Phase 1/2a study of PBP1510 administered to patients with advanced/metastatic pancreatic cancer. The study will be conducted in two parts, Part 1 as a PBP1510 single agent dose-escalation, and PBP1510 dose-escalation in combination with gemcitabine, and Part 2 as PBP1510 dose-expansion at the RP2D in combination with gemcitabine.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Chemotherapy
Other
Cancer type
Pancreatic Cancer
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Must have received: standard chemotherapy
advanced/metastatic pancreatic cancer patients whose tumours have progressed after at least one prior line of standard chemotherapy
Cannot have received: radiation therapy
Exception: allowed if to < 25% of bone marrow and completed at least 4 weeks before first dose
Patients currently receiving radiation therapy or those having received radiation within 4 weeks prior to study entry
Cannot have received: investigational anti-cancer drug
Patients having received investigational anti-cancer drug within 28 days (or 5 half-lives, whichever is longer) preceding the first dose of PBP1510
Cannot have received: chemotherapy
chemotherapy within the last 4 weeks prior to the first dose of PBP1510
Lab requirements
Blood counts
anc ≥ 1.5 × 10^9 /l; haemoglobin ≥ 9 g/dl; platelets ≥ 100 × 10^9 /l
Kidney function
serum creatinine or creatinine clearance (as determined by the cockcroft gault formula) or egfr based on mdrd ≤ 1.5 x uln or ≥ 50 ml/min or ≥ 50 ml/min/1.73 m^2
Liver function
total bilirubin ≤ 2 × uln (≤ 3 x uln for patients with biliary stenting and patients with gilbert's syndrome); ast and alt < 3 x uln (≤ 5 x uln for patients with hepatic metastases)
Cardiac function
lvef ≥ 50% by echo or muga; qtc ≤ 470 ms
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Northwell Health / R.J. Zuckerberg Cancer Center · New Hyde Park, New York
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT05141149 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior radiation therapy, investigational anti-cancer drug, chemotherapy disqualifies patients from enrollment.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages